Cargando…

Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis

Alzheimer disease (AD) is an increasingly common neurodegenerative disease, especially in countries with aging populations. Its diagnosis is complex and is usually carried out in advanced stages of the disease. In addition, lipids and oxidative stress have been related to AD since the earliest stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Peña-Bautista, Carmen, Álvarez-Sánchez, Lourdes, Ferrer, Inés, López-Nogueroles, Marina, Cañada-Martínez, Antonio José, Oger, Camille, Galano, Jean-Marie, Durand, Thierry, Baquero, Miguel, Cháfer-Pericás, Consuelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300760/
https://www.ncbi.nlm.nih.gov/pubmed/34209667
http://dx.doi.org/10.3390/antiox10071043
_version_ 1783726524855222272
author Peña-Bautista, Carmen
Álvarez-Sánchez, Lourdes
Ferrer, Inés
López-Nogueroles, Marina
Cañada-Martínez, Antonio José
Oger, Camille
Galano, Jean-Marie
Durand, Thierry
Baquero, Miguel
Cháfer-Pericás, Consuelo
author_facet Peña-Bautista, Carmen
Álvarez-Sánchez, Lourdes
Ferrer, Inés
López-Nogueroles, Marina
Cañada-Martínez, Antonio José
Oger, Camille
Galano, Jean-Marie
Durand, Thierry
Baquero, Miguel
Cháfer-Pericás, Consuelo
author_sort Peña-Bautista, Carmen
collection PubMed
description Alzheimer disease (AD) is an increasingly common neurodegenerative disease, especially in countries with aging populations. Its diagnosis is complex and is usually carried out in advanced stages of the disease. In addition, lipids and oxidative stress have been related to AD since the earliest stages. A diagnosis in the initial or preclinical stages of the disease could help in a more effective action of the treatments. Isoprostanoid biomarkers were determined in plasma samples from preclinical AD participants (n = 12) and healthy controls (n = 31) by chromatography and mass spectrometry (UPLC-MS/MS). Participants were accurately classified according to cerebrospinal fluid (CSF) biomarkers and neuropsychological examination. Isoprostanoid levels did not show differences between groups. However, some of them correlated with CSF biomarkers (t-tau, p-tau) and with cognitive decline. In addition, a panel including 10 biomarkers showed an area under curve (AUC) of 0.96 (0.903–1) and a validation AUC of 0.90 in preclinical AD prediction. Plasma isoprostanoids could be useful biomarkers in preclinical diagnosis for AD. However, these results would require a further validation with an external cohort.
format Online
Article
Text
id pubmed-8300760
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83007602021-07-24 Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis Peña-Bautista, Carmen Álvarez-Sánchez, Lourdes Ferrer, Inés López-Nogueroles, Marina Cañada-Martínez, Antonio José Oger, Camille Galano, Jean-Marie Durand, Thierry Baquero, Miguel Cháfer-Pericás, Consuelo Antioxidants (Basel) Article Alzheimer disease (AD) is an increasingly common neurodegenerative disease, especially in countries with aging populations. Its diagnosis is complex and is usually carried out in advanced stages of the disease. In addition, lipids and oxidative stress have been related to AD since the earliest stages. A diagnosis in the initial or preclinical stages of the disease could help in a more effective action of the treatments. Isoprostanoid biomarkers were determined in plasma samples from preclinical AD participants (n = 12) and healthy controls (n = 31) by chromatography and mass spectrometry (UPLC-MS/MS). Participants were accurately classified according to cerebrospinal fluid (CSF) biomarkers and neuropsychological examination. Isoprostanoid levels did not show differences between groups. However, some of them correlated with CSF biomarkers (t-tau, p-tau) and with cognitive decline. In addition, a panel including 10 biomarkers showed an area under curve (AUC) of 0.96 (0.903–1) and a validation AUC of 0.90 in preclinical AD prediction. Plasma isoprostanoids could be useful biomarkers in preclinical diagnosis for AD. However, these results would require a further validation with an external cohort. MDPI 2021-06-29 /pmc/articles/PMC8300760/ /pubmed/34209667 http://dx.doi.org/10.3390/antiox10071043 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peña-Bautista, Carmen
Álvarez-Sánchez, Lourdes
Ferrer, Inés
López-Nogueroles, Marina
Cañada-Martínez, Antonio José
Oger, Camille
Galano, Jean-Marie
Durand, Thierry
Baquero, Miguel
Cháfer-Pericás, Consuelo
Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
title Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
title_full Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
title_fullStr Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
title_full_unstemmed Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
title_short Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
title_sort lipid peroxidation assessment in preclinical alzheimer disease diagnosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300760/
https://www.ncbi.nlm.nih.gov/pubmed/34209667
http://dx.doi.org/10.3390/antiox10071043
work_keys_str_mv AT penabautistacarmen lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT alvarezsanchezlourdes lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT ferrerines lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT lopeznoguerolesmarina lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT canadamartinezantoniojose lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT ogercamille lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT galanojeanmarie lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT durandthierry lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT baqueromiguel lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis
AT chaferpericasconsuelo lipidperoxidationassessmentinpreclinicalalzheimerdiseasediagnosis